Literature DB >> 19528284

Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides.

Secondo Sonza1, Adam Johnson, David Tyssen, Tim Spelman, Gareth R Lewis, Jeremy R A Paull, Gilda Tachedjian.   

Abstract

Polyanion-based microbicides have been developed to prevent the sexual transmission of human immunodeficiency virus (HIV). Recent data suggest that polyanions have the capacity to enhance HIV type 1 (HIV-1) replication at threshold antiviral concentrations. Evaluation of the microbicide candidates SPL7013 and PRO 2000 revealed no specific enhancement of two CCR5 HIV-1 strains in human peripheral blood mononuclear cells compared to enfuvirtide (Fuzeon). The enhancement effect is likely to be a function of the assay conditions and is not an intrinsic property of these polyanions.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19528284      PMCID： PMC2715623          DOI： 10.1128/AAC.00102-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection.

Authors:  Sheila R Abner; Patricia C Guenthner; Jeannette Guarner; Kelly A Hancock; James E Cummins; Aaron Fink; G Thomas Gilmore; Charles Staley; Albert Ward; Odessa Ali; Sander Binderow; Stephen Cohen; Lisa A Grohskopf; Lynn Paxton; Clyde E Hart; Charlene S Dezzutti
Journal:  J Infect Dis       Date:  2005-09-26       Impact factor: 5.226

2.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Authors:  J M Kilby; S Hopkins; T M Venetta; B DiMassimo; G A Cloud; J Y Lee; L Alldredge; E Hunter; D Lambert; D Bolognesi; T Matthews; M R Johnson; M A Nowak; G M Shaw; M S Saag
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

3.  SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques.

Authors:  Yong-Hou Jiang; Peter Emau; J Scott Cairns; Leon Flanary; William R Morton; Tom D McCarthy; Che-Chung Tsai
Journal:  AIDS Res Hum Retroviruses       Date:  2005-03       Impact factor: 2.205

4.  Enhanced human immunodeficiency virus infection in macrophages by high-molecular-weight dextran sulfate is associated with conformational changes of gp120 and expression of the CCR5 receptor.

Authors:  P P Jagodzinski; A Wierzbicki; J Wustner; Y Kaneko; D Kozbor
Journal:  Viral Immunol       Date:  1999       Impact factor: 2.257

5.  Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer.

Authors:  Johanna Wapling; Katie L Moore; Secondo Sonza; Johnson Mak; Gilda Tachedjian
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis.

Authors:  Marcus Y Chen; Iona Y Millwood; Handan Wand; Mary Poynten; Matthew Law; John M Kaldor; Steve Wesselingh; Clare F Price; Laura J Clark; Jeremy R A Paull; Christopher K Fairley
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

7.  Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.

Authors:  P R Meylan; R S Kornbluth; I Zbinden; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes.

Authors:  D I Bernstein; L R Stanberry; S Sacks; N K Ayisi; Y H Gong; J Ireland; R J Mumper; G Holan; B Matthews; T McCarthy; N Bourne
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  Mononuclear cell adherence induces neutrophil chemotactic factor/interleukin-8 gene expression.

Authors:  K Kasahara; R M Strieter; S W Chensue; T J Standiford; S L Kunkel
Journal:  J Leukoc Biol       Date:  1991-09       Impact factor: 4.962

10.  Polyanionic microbicides modify Toll-like receptor-mediated cervicovaginal immune responses.

Authors:  R T Trifonova; G F Doncel; R N Fichorova
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191
View more
  5 in total

1.  Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.

Authors:  Sushama Telwatte; Katie Moore; Adam Johnson; David Tyssen; Jasminka Sterjovski; Muriel Aldunate; Paul R Gorry; Paul A Ramsland; Gareth R Lewis; Jeremy R A Paull; Secondo Sonza; Gilda Tachedjian
Journal:  Antiviral Res       Date:  2011-04-01       Impact factor: 5.970

2.  Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Authors:  David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

3.  SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

Authors:  Clare F Price; David Tyssen; Secondo Sonza; Ashley Davie; Sonya Evans; Gareth R Lewis; Shirley Xia; Tim Spelman; Peter Hodsman; Thomas R Moench; Andrew Humberstone; Jeremy R A Paull; Gilda Tachedjian
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

4.  Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1.

Authors:  Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Fred C Krebs
Journal:  Virol J       Date:  2012-01-26       Impact factor: 4.099

Review 5.  Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.

Authors:  Fernando Notario-Pérez; Roberto Ruiz-Caro; María-Dolores Veiga-Ochoa
Journal:  Drug Des Devel Ther       Date:  2017-06-15       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.